

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Fostemsavir for treating multidrug resistant HIV-1 ID2726

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • ViiV Healthcare (fostemsavir) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • African Advocacy Foundation • African Health Policy Network • Black Health Agency • GMFA – The Gay Men’s Health Charity • Haemophilia Society • HIV-i-Base • LGBT Foundation • Muslim Council of Britain • NAM Publications • National AIDS Trust • NAZ • Positively UK • South Asian Health Action • South Asian Health Foundation • Specialised Healthcare Alliance • Terrence Higgins Trust • UK-CAB <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Clinical Biochemists – Microbiology Section • British Association for Psychopharmacology • British Association for Sexual Health and HIV • British Geriatrics Society • British HIV Association • British Infection Association • Community Practitioners’ & Health Visitors Association • HIVPA • Infection Prevention Society • Medical Foundation for AIDS & Sexual Health • Microbiology Society • National HIV Nurses Association • Positive Prevention Plus 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Haemophilia Wales • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (lopinavir, ritonavir) • Accord (atazanavir, darunavir, efavirenz, emtricitabine, lamivudine, lopinavir, nevirapine, ritonavir, tenofovir) • Amneal Pharma (abacavir, lamivudine) • Aurobindo Pharma (efavirenz, lamivudine, nevirapine, tenofovir, zidovudine) • BMS (atazanavir, cobicistat, efavirenz) • Boehringer Ingelheim (nevirapine, tipranavir) • Cipla (lamivudine, tenofovir) • Dr Reddy’s Laboratories (abacavir, atazanavir, darunavir, efavirenz, emtricitabine, lamivudine, nevirapine, tenofovir) • Gilead (bictegravir, cobicistat, efavirenz, elvitegravir, emtricitabine, rilpivirine, tenofovir)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Psychiatrists • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Clinical Virology Network • UK Primary Immunodeficiency Network <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Enfield CCG • NHS Coventry and Rugby CCG • Welsh Government 	<ul style="list-style-type: none"> • GlaxoSmithKline (lamivudine) • Glenmark Pharmaceuticals (abacavir, emtricitabine, lamivudine, tenofovir) • Janssen (cobicistat, darunavir, emtricitabine, etravirine, rilpivirine, tenofovir) • Lupin (abacavir, emtricitabine, lamivudine, tenofovir) • Mylan (abacavir, atazanavir, darunavir, efavirenz, emtricitabine, lamivudine, lopinavir, nevirapine, ritonavir, tenofovir, zidovudine) • MSD (doravirine, lamivudine, raltegravir, tenofovir) • Roche (enfuvirtide) • Sandoz (atazanavir, efavirenz, emtricitabine, tenofovir) • Sun Pharma (abacavir, lamivudine) • ViiV Healthcare (abacavir, dolutegravir, fosamprenavir, lamivudine, rilpivirine, zidovudine) • Wockhardt (nevirapine) • Zentiva (abacavir, atazanavir, darunavir, efavirenz, emtricitabine, lamivudine, tenofovir) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Infectious Diseases Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • UCL Centre for Sexual Health & HIV Research • UK National Screening Committee <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.